Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 16/20 | 0.49 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.47 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.42 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.42 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.42 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.42 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | PGR | P06401 | 1/20 | 0.40 |
| ▸ | NOS3 | P29474 | 1/20 | 0.39 |
| ▸ | NOS1 | P29475 | 1/20 | 0.39 |
| ▸ | NOS2 | P35228 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7494225 | 0.86 | CYP2A6 (0.43) | HRH3CYP2A6PGRNOS3NOS1 | |
| SCHEMBL5032985 | 0.86 | HRH3 (0.58) | HRH3CYP2A6KCNH2 | |
| SCHEMBL5032875 | 0.86 | HRH3 (0.51) | HRH3CYP2A6CHRM2CHRM4CHRM5 | |
| SCHEMBL5034855 | 0.83 | HRH3 (0.55) | HRH3CYP2A6KCNH2 | |
| SCHEMBL176970 | 0.83 | HRH3 (0.49) | HRH3CYP2A6CHRM2CHRM4CHRM5 | |
| SCHEMBL2093469 | 0.83 | HRH3 (0.49) | HRH3CYP2A6CHRM2CHRM4CHRM5 | |
| SCHEMBL13079657 | 0.83 | HRH3 (0.52) | HRH3CYP2A6CHRM2CHRM4CHRM5 | |
| SCHEMBL5032790 | 0.83 | HRH3 (0.55) | HRH3CYP2A6KCNH2 | |
| SCHEMBL5030411 | 0.81 | HRH3 (0.54) | HRH3CYP2A6KCNH2 | |
| SCHEMBL5796888 | 0.80 | HRH3 (0.50) | HRH3CYP2A6CHRM2CHRM4CHRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6867299-B2 | Inosine monophosphate dehydrogenase (IMPDH); use as immunosuppressants, anticancer agents and antiviral agents | HOFFMANN-LA ROCHE INC. (US) | 2005-03-15 | — | — | US | disclosed |
| US-20020052513-A1 | Oxamide IMPDH inhibitors | HOFFMANN-LA ROCHE INC. | 2002-05-02 | — | — | US | disclosed |
| EP-1127883-A2 | Oxamides as IMPDH inhibitors | F. HOFFMANN-LA ROCHE AG (CH) | 2001-08-29 | — | — | EP | disclosed |
| EP-0906282-A1 | HETEROCYCLYLMETHYLAMINO DERIVATIVES OF CYCLOBUTENE-3,4-DIONES AS POTASSIUM CHANNEL MODULATORS | AMERICAN HOME PRODUCTS CORPORATION (US) | 1999-04-07 | — | — | EP | disclosed |
| US-5872139-A | MUSCLE RELAXANTS USED TO TREAT URINARY INCONTINENCE, IRRITABLE BOWEL SYNDROME, ASTHMA, PREMATURE LABOR, CONGESTIVE HEART FAILURE, ANGINA, CEREBRAL VASCULAR DISEASE AND HYPERTENSION | AMERICAN HOME PRODUCTS CORPORATION (US) | 1999-02-16 | — | — | US | disclosed |
| WO-1997048682-A1 | HETEROCYCLYLMETHYLAMINO DERIVATIVES OF CYCLOBUTENE-3,4-DIONES AS POTASSIUM CHANNEL MODULATORS | AMERICAN HOME PRODUCTS CORPORATION (US) | 1997-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020052513-A1 | Oxamide IMPDH inhibitors | IMPDH1, IMPDH2, IMPA1 | HRH3 2918/4885CYP2A6 845/4885CHRM2 4148/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.